Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CMO Joakim Wijkstrom sold 30,800 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $8.27, for a total value of $254,716.00. Following the completion of the transaction, the chief marketing officer directly owned 333,469 shares of the company’s stock, valued at approximately $2,757,788.63. The trade was a 8.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Vanda Pharmaceuticals Stock Down 2.1%

Shares of NASDAQ VNDA traded down $0.17 during mid-day trading on Thursday, reaching $8.03. 221,009 shares of the company were exchanged, compared to its average volume of 2,844,654. Vanda Pharmaceuticals Inc. has a 1 year low of $3.81 and a 1 year high of $9.60. The firm has a 50-day moving average of $7.56 and a 200 day moving average of $5.97. The stock has a market cap of $474.65 million, a price-to-earnings ratio of -2.15 and a beta of 0.55. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) EPS for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The firm had revenue of $57.22 million during the quarter, compared to the consensus estimate of $59.28 million. On average, research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Torren Management LLC acquired a new position in shares of Vanda Pharmaceuticals in the fourth quarter valued at about $25,000. Bailard Inc. lifted its holdings in shares of Vanda Pharmaceuticals by 16.2% during the second quarter. Bailard Inc. now owns 26,100 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 3,631 shares during the period. Panagora Asset Management Inc. boosted its position in Vanda Pharmaceuticals by 3.4% in the fourth quarter. Panagora Asset Management Inc. now owns 118,987 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 3,928 shares during the last quarter. Jane Street Group LLC increased its holdings in Vanda Pharmaceuticals by 6.1% in the 2nd quarter. Jane Street Group LLC now owns 79,107 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 4,533 shares during the period. Finally, Savant Capital LLC increased its holdings in Vanda Pharmaceuticals by 30.3% in the 3rd quarter. Savant Capital LLC now owns 22,493 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 5,229 shares during the period. Institutional investors and hedge funds own 88.14% of the company’s stock.

Vanda Pharmaceuticals News Roundup

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA granted a formal evidentiary public hearing to review CDER’s proposed refusal to approve Vanda’s sNDA for HETLIOZ in jet‑lag disorder — a rare, high‑visibility procedural win that gives Vanda a public forum to challenge the refusal and could materially improve approval odds if the hearing goes well. Vanda Announces FDA Grants Landmark Hearing for HETLIOZ
• Positive Sentiment: Truist initiated coverage with a “Buy” rating and an $18 price target (~119% upside vs. current levels) — a new bullish analyst voice that can attract buyers and volume. Truist starts Vanda at Buy $18 (Benzinga)
• Positive Sentiment: HC Wainwright reiterated a Buy and published 2027 quarterly EPS forecasts (and a $24 price target) — another sizable upside target that supports constructive sentiment among growth/biotech investors. HC Wainwright issues estimates, Buy $24 PT
• Neutral Sentiment: Analyst coverage is mixed: while several firms maintain Buy/Overweight calls and high targets, there are recent downgrades and a consensus “Moderate Buy” with an average target near $14.90 — constructive overall but not unanimous. MarketBeat analyst summary
• Negative Sentiment: Multiple senior insiders sold sizable blocks of shares on/around March 2 (CEO, CFO, CMO, and SVPs combined disclosed sales totaling roughly $2.6M+) — coordinated insider selling often creates short‑term supply and can be perceived negatively by the market. Vanda’s Top Brass Quietly Unload a Wave of Shares (TipRanks)
• Negative Sentiment: SEC filings formally disclose the individual insider trades (CEO filing and others), making the sales official and giving investors precise sizes/prices to evaluate motives (tax, diversification, or signal). SEC filing — CEO ownership disclosure

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. HC Wainwright lifted their price target on shares of Vanda Pharmaceuticals from $22.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Wednesday, January 21st. UBS Group restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Truist Financial assumed coverage on Vanda Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $18.00 target price on the stock. Finally, Wall Street Zen cut Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 14th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Vanda Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $14.90.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.